The trails of preventing deterioration of DLBCL

Recently, a new therapeutic drug is in its clinical Phase II experiments. The drug is mainly for those patients with deterioration of diffuse large B-cell lymphoma (DLBCL), because most of these patients will show tumor metastasis over time. The main target of this drug is histone modifying enzyme, and this target shows obvious effect on some tumor with genetic variation. The design of experiments was mainly done by Sarit Assouline, a blood disease oncologist in Jewish hospital and he is also very interested in producing recombinant proteins like recombinant horse proteins. And the research results have been published in Blood, which is the top journal in Hematology.

Dr. Assouline, associate professor of medical oncology at McGill University said, "DLBCL is a relatively common form in lymphoma and has relatively-high invasiveness. With the deterioration of the disease, there is no effective clinical treatment. The patients have an average life expectancy of 6 months. Our task is to find a new specific target in turn to improve the prognosis of patients, but many clinical trials are just focusing on the patient's response to different treatments. Our aim is to be able to better improve the effectiveness of the treatment on the basis of understanding the mechanism of disease."

Among DLBCL patients, up to 40% of them who receive conventional chemical immunotherapy, stem cell transplantation or several joint treatments still show no effects. New treatment method has a stronger against nature on the basis of deeply explaining molecular structures. Almost all of DLBCL patients contain mutations of histone modifying enzyme gene, so histone acetyl transferase inhibitors have a significant effect on the level of improving the treatment of patients.

In the experiment, subjects went through complex genetic analysis and strict distinction. 28% of patients respond well to the above treatment, and the expression of MEF2B gene was closely related to the curative effect of patients. By analysis of collected biopsy and blood samples, the study revealed that this drug can affect a series of proteins in the body of these patients. If we can take advantage of the latest diagnostic technology to assist, the effect will be better. Flarebio provides superior recombinant proteins like recombinant NRG3 at competitive prices.